New Evidence Against Use of Fluoroquinolones in Aortic Disea
Patients with aortic dissection (AD) or aortic aneurysm (AA) should not be given fluoroquinolones unless no other treatment options are available, the authors of a new report conclude.

Recent population-based studies have revealed that the use of fluoroquinolones (FQs) is associated with an increased risk of aortic dissection (AD) and aneurysm (AA). However, no evidence is available on whether FQs increase adverse events in patients who had been diagnosed with AD or AA.

This study investigated whether the use of FQs increases the risk of aortic-related adverse events and death in this high-risk population.

A retrospective cohort study was conducted by using the Taiwan National Health Insurance Research Database. A total of 31,570 adult patients who survived after admission for AD or AA were identified. They divided each calendar year into 6 data units (2 months) for each patient and each year during follow-up. Covariates and exposure of interest (FQs) were reassessed every 2 months. They used another common antibiotic, amoxicillin, as a negative control exposure.

-- Exposure to FQs was associated with a higher risk of all-cause death, aortic death, and later aortic surgery.

-- However, amoxicillin exposure was not significantly associated with risk of any of the outcomes.

-- A subgroup analysis revealed that the effect of FQs was not significantly different between the AD and AA groups.

Conclusively, relative to amoxicillin use, FQ exposure in patients with AD or AA was associated with a higher risk of adverse outcomes. FQs should not be used by high-risk patients unless no other treatment options are available.